Orexo´s treatment for incontinence/nocturia entering Phase I

FOR MEDIA INFORMATION Simon Vane Percy / Sarah Roberts Vane Percy & Roberts (T) +44 (0)1737 821891 / 892 (F) +44 (0)1737 821899 (e) simon@vanepercy.com / sarah@vanepercy.com Orexo’s product for nocturia and on demand treatment of urinary incontinence, OX 19 (sublingual desmopressin) has started phase 1 trials. Orexo has developed several formulations and is now proceeding to investigate the lead formulation. The bioavailability trial, which is taking place in Sweden, is expected to be completed by the end of this year. OX 19 exploits Orexo’s novel sublingual tablet technology which enables rapid and reliable onset of action.

For further information contact:

Zsolt Lavotha, President & CEO
Tel: +46 (0)18 780 88 12
Email: zsolt.lavotha@orexo.se

Claes Wenthzel, Executive Vice President & CFO
Tel: +46 (0)18 780 88 44
Email: claes.wenthzel@orexo.se